April 29, 2016

The Duke Human Vaccine Institute Appoints New Associate Director of the Duke Human Vaccine Institute and Senior Director of Product Development

The Duke Human Vaccine Institute Appoints New Associate Director of the Duke Human Vaccine Institute and Senior Director of Product Development

DURHAM, N.C. - The Duke Human Vaccine Institute (DHVI) has appointed Dr. Frederick W. Porter as the new Associate Director of the Duke Human Vaccine Institute and Senior Director of Product Development. Dr. Porter’s primary focus within his role will be to further develop and support growth of the Current Good Manufacturing Practice (CGMP) Facility.

Dr. Porter comes to the DHVI with 15 years of experience in research and development (R&D) of vaccines and biopharmaceuticals. Additionally, Dr. Porter has a proven track record of advancing novel candidates and production platforms from discovery to the clinic including: cell culture based viral vaccines, next-generation reverse genetics platforms, CHO expressed recombinant protein vaccines and RNA vaccines. With senior level management experience in both academia and industry, Dr. Porter brings a unique perspective and ability to provide and implement high quality management of the new CGMP facility. As Head of Drug Substance R&D at Glaxosmithkline (GSK), Dr. Porter led a global technical development team responsible for antigen manufacturing processes development for the GSK Vaccine product portfolio. His R&D expertise includes production and characterization of vaccines, gene therapy vectors, nucleic acid and recombinant protein therapeutics. 

Dr. Porter holds a PhD in Biochemistry from The University of Wisconsin-Madison, a M.S. in Microbiology from Seton Hall University, and a B.S. in Biochemistry from Rutgers University.                        

Thomas Denny, DHVI COO said, “Having a CGMP facility and Frederick Porter as part of the DHVI team, makes us one of the most globally advanced vaccine institutes in the country. It positions the DHVI teams to advance our HIV vaccine development efforts, while having an infrastructure to respond to emerging public health threats.”